The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shikeeva A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Molecular genetic aspects of non-small cell lung cancer

Authors:

Shikeeva A.A., Kekeeva T.V., Zavalishina L.É., Andreeva Yu.Yu., Frank G.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(5): 56‑61

Views: 3706

Downloaded: 186

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Shikeeva AA, Kekeeva TV, Zavalishina LÉ, Andreeva YuYu, Frank GA. Molecular genetic aspects of non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2013;2(5):56‑61. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
Resu­lts of inva­sive diagnosis of primary mali­gnant bone tumors of the pelvis. P.A. Herzen Journal of Onco­logy. 2024;(2):9-14
Modern treatment methods for patients with liver meta­stases from uveal mela­noma. P.A. Herzen Journal of Onco­logy. 2024;(2):74-84
Headache chro­nification: analysis of evoked pote­ntials for stimulus. Russian Journal of Pain. 2024;(1):18-26
Successful combinations of drug and non-drug therapy for low back pain. Russian Journal of Pain. 2024;(1):57-67
Possibilities of dyna­mic phase contrast MRI of cere­brospinal fluid for performing a tap test in a patient with idiopathic normotensive hydrocephalus. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):148-153
The normal sono­graphic picture of the para­tonsillar region and the prerequisites for ultrasound diagnosis of puru­lent pathology of the pharynx. Russian Bulletin of Otorhinolaryngology. 2024;(1):4-9
Methods of pancreatic fibrosis asse­ssment. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):48-57
Comparison of the clinical performance of immu­nochromatographic tests for the dete­ction of SARS-CoV-2 anti­gens with data from inde­pendent studies. Labo­ratory Service. 2024;(1):13-19
Pathogenetic, clinical-diagnostic and therapeutic aspe­cts of premenstrual syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):37-42
Traumatic damage to the diaphragm in children. Piro­gov Russian Journal of Surgery. 2024;(4):64-68

Lung cancer (LC) is one of the most common cancers and one of the major causes of death in cancer patients. Not only the clinical characteristics of a patient, the histological type and grade of a tumor, but also its molecular genetic features are recently of fundamental importance due to the elaboration of a personalized approach to choosing the management tactics for cancer patients. Lung cancer is characterized by various genetic alterations in the tumor growth suppressor genes and oncogenes, such as HLJ1 (1p31), FHIT (3p14), p16INK4a (9p21), RASSF1A, FUS1, LIMD1, SAMA3B, SEMA3F (3p21), and p53 (17p13). Each histological type is shown to have also its characteristic profile of genetic changes; thus, EGFR and KRAS gene mutations, EML4/ALK translocation, chromosomal rearrangements in the regions 2p, 9p, 14q, and 20 were characteristic for lung adenocarcinomas; FGFR1 and SOX2 gene amplification and chromosomal arrangements in the regions 3p and 17p are shown for squamous cell lung cancer. Studies in the molecular biology of non-small cell lung cancer (NSCLC) give an insight into and evaluate the possibilities of using certain genetic disorders in clinical practice. This review considers molecular genetic changes in NSCLC and their use for the diagnosis and prognosis of the disease and for the determination of susceptibility to targeted therapy.

Keywords:

non-small cell lung cancer
molecular genetic changes
targeted therapy
diagnosis
prognostic markers

Authors:

Shikeeva A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

List of references:

  1. Ahrendt S.A., Decker P.A., Doffek K., Wang B., Xu L., Demeure M.J. et al. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res. 2000; 60 (9): 2488-91.
  2. Girard L., Zöchbauer-Müller S., Virmani A.K., Gazdar A.F., Minna J.D. Genomewide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000; 60 (17): 4894-906.
  3. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Sugio K. et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin. Cancer Res. 1996; 2 (7): 1185-9.
  4. Tseng R.C., Chang J.W., Hsien F.J., Chang Y.H., Hsiao C.F., Chen J.T. et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int. J. Cancer. 2005; 117 (2): 241-7.
  5. Woenckhaus M., Grepmeier U., Wild P.J., Merk J., Pfeifer M., Woenckhaus U. et al. Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium. Am. J. Clin. Pathol. 2005; 123 (5): 752-61.
  6. Zhou X., Kemp B.L., Khuri F.R., Liu D., Lee J.J., Wu W. et al. Prognostic implication of microsatellite profiles in early-stage non-small cell lung cancer. Clin. Cancer Res. 2000; 6 (2): 559- 65.
  7. Sanchez-Cespedes M., Ahrendt S.A., Piantadosi S., Rosell R., Monzo M., Wu L. et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 2001; 61 (4): 1309-13.
  8. Sanchez-Cespedes M., Decker P.A., Doffek K.M., Esteller M., Westra W.H., Alawi E.A. et al. Increased loss of chromosome 9p21 but not P16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 2001; 61 (5): 2092-6.
  9. Marsit C.J., Wiencke J.K., Nelson H.H., Kim D.H., Hinds P.W., Aldape K. et al. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genet. Cytogenet. 2005; 162 (2): 115-21.
  10. Hirao T., Nelson H.H., Ashok T.D., Wain J.C., Mark E.J., Christiani D.C. et al. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res. 2001; 61 (2): 612-5.
  11. Grepmeier U., Dietmaier W., Merk J., Wild P.J., Obermann E.C., Pfeifer M. et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int. J. Oncol. 2005; 27 (2): 481-8.
  12. Pan H., Califano J., Ponte J.F., Russo A.L., Cheng K.H., Thiagalingam A. et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res. 2005; 65 (5): 1664-9.
  13. Wrage M., Ruosaari S., Eijk P.P., Kaifi J.T., Hollmén J., Yekebas E.F. et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin. Cancer Res. 2009; 15 (5): 1566-74.
  14. Chmara M., Wozniak A., Ochman K., Kobierska G., Dziadziuszko R., Sosinska-Mielcarek K. et al. Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. Anticancer Res. 2004; 24 (6): 4259-63.
  15. Mitsuuchi Y., Testa J.R. Cytogenetics and molecular genetics of lung cancer. Am. J. Med. Genet. 2002; 115: 183-8.
  16. Sekido Y., Fong K.M., Minna J.D. Molecular genetics of lung cancer. Ann. Rev. Med. 2003; 54: 73-87.
  17. Zienolddiny S., Ryberg D., Arab M.O., Skaug V., Haugen A. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br. J. Cancer. 2001; 84 (2): 226-31.
  18. Zochbauer-Muller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Ann. Rev. Physiol. 2002; 64: 681-708.
  19. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450 (7171): 893-8.
  20. Sos M.L., Thomas R.K. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene. 2012; 31 (46): 4811-4. doi: 10.1038/onc.2011.640.
  21. Wen J., Fu J., Zhang W., Guo M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod. Pathol. 2011; 24 (7): 932-43.
  22. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995; 19: 183-232.
  23. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epider- mal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350 (21): 2129-39.
  24. Paez J.G., Jänne P.A., Lee J.C. et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304 (5676): 1497-500.
  25. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer. 2007; 7 (3): 169-81.
  26. Bell D.W., Brannigan B.W., Matsuo K. et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin. Cancer Res. 2008; 14: 4079-84.
  27. Cappuzzo F., Ciuleanu T., Stelmakh L. et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11 (6): 521-9.
  28. Lee D., Kim S.-W., Suh C., Han Y., Lee J.-S. Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother. Pharmacol. 2011; 67 (1): 35-9.
  29. Roberts P.J., Stinchcombe T.E., Der C.J., Socinski M.A. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 2010; 28: 4769-77.
  30. Ihle N.T., Byers L.A., Kim E.S. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst. 2012; 104: 228-39.
  31. Herbst R.S., Kelly K., Chansky K. et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J. Clin. Oncol. 2010; 28: 4747-54.
  32. Li M., Liu L., Liu Z. et al. The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol. Rep. 2009; 22: 1013-20.
  33. Riely G.J., Kris M.G., Rosenbaum D. et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 2008; 14: 5731-4.
  34. Linardou H., Dahabreh I.J., Kanaloupiti D. et al. Assessment of somatic K-ras mutations as a mechanism associated with resistance to egfr-targeted agents: a systematic review and me- ta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9: 962-72.
  35. Paik P.K., Arcila M.E., Fara M. et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 2011; 29: 2046-51.
  36. Marchetti A., Felicioni L., Malatesta S. et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 2011; 29: 3574-9.
  37. Kawano O., Sasaki H., Endo K. et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006; 54: 209-15.
  38. Steele N.L., Plumb J.A., Vidal L. et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumour. Clin. Cancer Res. 2008; 14: 804-10.
  39. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The pten/pi3k/Akt signaling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets. 2008; 8: 187-98.
  40. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009; 6: 587-95.
  41. Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-6.
  42. Bergethon K., Shaw A.T., Ou S.H. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012; 30: 863-70.
  43. Davies K.D., Le A.T., Theodoro M.F. et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 2012; 18 (17): 4570-9.
  44. Rimkunas V.M., Crosby K.E., Li D., Hu Y., Kelly M.E., Gu T.L. et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin. Cancer Res. 2012; 18 (16): 4449-57.
  45. Aisner D.L., Marshall C.B. Molecular pathology of non-small cell lung cancer. A Practical Guide. Am. J. Clin. Pathol. 2012; 138: 332-46.
  46. Bean J., Brennan C., Shih J.-Y. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007; 104 (52): 20932-7.
  47. Engelman J.A., Zejnullahu K., Mitsudomi T. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007; 316: 1039-43.
  48. Weiss J., Sos M.L., Seidel D. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2010; 2 (62): 62ra93.
  49. Junker K., Stachetzki U., Rademacher D. et al. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer. 2005; 48: 59-67.
  50. Ramieri M.T., Murari R., Botti C. et al. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res. 2010; 30: 1287-92.
  51. Li C., Sun Y., Fang R. et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J. Thorac. Oncol. 2012; 7: 85-9.
  52. Tomizawa K., Suda K., Onozato R. et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011; 74: 139-44.
  53. Shigematsu H., Takahashi T., Nomura M. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005; 65: 1642-6.
  54. Heller G., Zielinski C.C., Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010; 29: 95-107.
  55. Ji M., Zhang Y., Shi D., Hou P. Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn. Pathol. 2011; 6: 48.
  56. Buckingham L., Penfield Faber L., Kim A. et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II non-small cell lung cancer patients. Int. J. Cancer. 2010; 126: 1630-9.
  57. Vaissiere T., Hung R.J., Zaridze D. et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009; 69: 243-52.
  58. Tessema M., Yu Y.Y., Stidley C.A. et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis. 2009; 30: 1132-8.
  59. Lin Q., Geng J., Ma K. et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not P16ink4a, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J. Cancer Res. Clin. Oncol. 2009; 135: 1675-84.
  60. Chen H., Suzuki M., Nakamura Y. et al. Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer. 2005; 50: 43-9.
  61. Begum S., Brait M., Dasgupta S., Ostrow K.L., Zahurak M., Carvalho A.L. et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 2011; 17 (13); 4494-503.
  62. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
  63. Bandi N., Zbinden S., Gugger M. et al. Mir-15a and Mir-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009; 69: 5553-9.
  64. Cha S.T., Chen P.S., Johansson G. et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 2010; 70: 2675-85.
  65. Crawford M., Batte K., Yu L. et al. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 2009; 388: 483-9.
  66. He X., Duan C., Chen J. et al. Let-7a elevates P21 (WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett. 2009; 583 (21): 3501-7.
  67. Liu B., Peng X.C., Zheng X.L. et al. Mir-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009; 66: 169-75.
  68. Liu X., Sempere L.F., Ouyang H. et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 2010; 120: 1298-309.
  69. Sun Y., Bai Y., Zhang F. et al. Mir-126 inhibits non- small cell lung cancer cells proliferation by targeting EGFL7. Biochem. Biophys. Res. Commun. 2010; 391: 1483-9.
  70. Bishop J.A., Benjamin H., Cholakh H. et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin. Cancer Res. 2010; 16: 610-9.
  71. Lebanony D., Benjamin H., Gilad S. et al. Diagnostic assay based on Hsa-Mir-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 2009; 27 (12): 2030-7.
  72. Markou A., Tsaroucha E.G., Kaklamanis L. et al. Prognostic value of mature microRNA-21 and micro-RNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008; 54: 1696-704.
  73. Raponi M., Dossey L., Jatkoe T. et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009; 69: 5776-83.
  74. Yanaihara N., Caplen N., Bowman E. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-98.
  75. Takamizawa J., Konishi H., Yanagisawa K. et al. Reduced expression of the Let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64: 3753-6.
  76. Gallardo E., Navarro A., Vinolas N. et al. Mir-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30: 1903-9.
  77. Yu S.L., Chen H.Y., Chang G.C. et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13: 48-57.
  78. Mitchell P.S., Parkin R.K., Kroh E.M. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl. Acad Sci USA. 2008; 105: 10513-8.
  79. Chang Y.L., Wu C.T., Lin S.C., Hsiao C.F., Jou Y.S., Lee Y.C. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin. Cancer Res. 2007; 13: 52-8.
  80. Gazdar A.F., Minna J.D. Multifocal lung cancers-clonality vs field cancerization and does it matter? J. Natl. Cancer Inst. 2009; 101: 541-3.
  81. Girard N., Ostrovnaya I., Lau C., Park B., Ladanyi M., Finley D. et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin. Cancer Res. 2009; 15: 5184-90.
  82. Shimizu S., Yatabe Y., Koshikawa T., Haruki N., Hatooka S., Shinoda M. et al. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin. Cancer Res. 2000; 6: 3994-9.
  83. Warth A., Macher-Goeppinger S., Muley T., Thomas M., Hoffmann H., Schnabel P.A. et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur. Respir. J. 2012; 39: 1437-42.
  84. Geurts-Giele W.R., Dirkx-van der Velden A.W., Bartalits N.M., Verhoog L.C., Hanselaar W.E., Dinjens W.N. Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing. Virchows Arch. 2013; 462 (2): 249-54.
  85. Takamochi K., Oh S., Matsuoka J., Suzuki K. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012; 75: 313-20.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.